Consultation: risankizumab for Crohn’s disease (30 day TA)
The North East and North Cumbria (NENC) Medicines Committee are seeking NENC system-wide views on implementation of NICE TA888: Risankizumab for previously treated moderately to severely active Crohn’s disease, as outlined in the attached consultation document.
Comments are welcomed from across the system, including residents and patients of the NENC. Comments will be returned to the medicines committee, or its sub-committee, and used to inform implementation of the decisions in NENC.
Please use this form to submit comments. All comments will be reviewed but please do not expect a personal response as we do not routinely reply to all comments. It is important to include any relevant evidence to back up any suggestions and please keep comments concise where possible.
- The messages sent from this form are transmitted via our hosts web server. If you have any security concerns about this process you can send your comments/feedback using your own email client to email@example.com.
- This consultation will run for four weeks and closes at 5pm on Wednesday 14th June 2023.
|NENC 30 day TA consultation - risankizumab for Crohn's disease||015 NENC 30 day TA Consultation - NICE TA888 - Risankizumab - May 2023||Draft for consultation|